Site History - Wacker Chemie AG

Site History

Company History: Wacker Biotech GmbH

1988 The state-owned Gene Technology Pilot Plant (GPA) starts operations at the Central Institute for Microbiology and Experimental Therapy (ZIMET) on the Beutenberg Campus in Jena. Focus on bioprocess development for the production of biopharmaceuticals in recombinant microorganisms.
1990 The GPA develops a high-cell-density fermentation process in E. coli, later patented and marketed as WACKER’s DENSETEC® technology.
1992 Inception of the state-owned Hans Knöll Institute (HKI) on the Beutenberg Campus in Jena. The GPA becomes a department of the HKI.
1995 The HKI (GPA) is granted GMP manufacturing authorization for the production of a recombinant protein therapeutic for clinical trials.
1999 Inception of the company ProThera GmbH on the Beutenberg Campus in Jena, as spin-off of the HKI and direct successor of the GPA. Focus on GMP-compliant contract manufacturing of therapeutic proteins in microorganisms.
2005 Wacker Chemie AG takes over ProThera GmbH. The company is renamed Wacker Biotech GmbH.
Inception of the company Scil Proteins Production GmbH on the Weinberg Campus in Halle (Saale). Focus on GMP-compliant contract manufacturing of therapeutic proteins in microorganisms.
2006 Market launch of ESETEC®, WACKER’s innovative E. coli secretion technology for the cost-effective production of therapeutic proteins.
2007 Scil Proteins Production GmbH opens GMP facility in Halle. The facility has 1,500-liter upstream capacity and matching downstream equipment. Expertise in protein refolding.
2009 Construction of a new warehouse and a new laboratory and administration building on the Beutenberg Campus site in Jena.
2010 Complete reconstruction and extension of the production building (former GPA building) in Jena according to current GMP requirements.
2012 Scil Proteins Production receives EMA approval for the commercial production of Reteplase (trade names Rapilysin®/Retavase®).
2014 Wacker Biotech acquires Scil Proteins Production GmbH, thus doubling its capacity for process development and production, and adds substantial refolding expertise to the technology portfolio.
2018 WACKER takes over SynCo Bio Partners Luxembourg S.à r.l., the pharmaceutical facility for microbial GMP production in the Netherlands, which has been operating under the name Wacker Biotech B.V. since November. The site in Amsterdam is acquired for the manufacture of biopharmaceuticals, live microbial products and vaccines, as well as the associated business.


Wacker Biotech GmbH
Jena and Halle (Germany)
Tel. +49 3641 5348-150

Wacker Biotech B.V.
Amsterdam (the Netherlands)
Tel. +31 20 750 3600